Amineptine in the treatment of amphetamine withdrawal: a placebo-controlled, randomised, double-blind study. 1997

J Jittiwutikan, and M Srisurapanont, and N Jarusuraisin
Northern Drug Dependence Treatment Centre, Chiang Mai, Thailand.

Temporary inability to function without amphetamine and the experience of withdrawal syndrome enhance the tendency for repetitive use. The investigators proposed to examine the therapeutic effects of amineptine, an antidepressant with dopamine reuptake inhibition effect, for the treatment of amphetamine withdrawal. The 14-day study was carried out on a randomised, double-blind, placebo-controlled design. The authors assessed the severity of amphetamine withdrawal syndrome by using two measures and performed both end-point and intent-to-treat analyses. The results showed that amineptine helped relieve a depressed mood within one week and improved the general condition within 2 weeks. In conclusion, amineptine is effective in rapid relief of depressed mood and improves the general condition of patients with amphetamine withdrawal. Since the amphetamine withdrawal may last for several weeks, studies with longer duration should be conducted before incorporating amineptine into the clinical practice a of amphetamine withdrawal treatment.

UI MeSH Term Description Entries
D008297 Male Males
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D003863 Depression Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders. Depressive Symptoms,Emotional Depression,Depression, Emotional,Depressive Symptom,Symptom, Depressive
D003986 Dibenzocycloheptenes A family of tricyclic hydrocarbons whose members include many of the commonly used tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC).
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013375 Substance Withdrawal Syndrome Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug. Drug Withdrawal Symptoms,Withdrawal Symptoms,Drug Withdrawal Symptom,Substance Withdrawal Syndromes,Symptom, Drug Withdrawal,Symptom, Withdrawal,Symptoms, Drug Withdrawal,Symptoms, Withdrawal,Syndrome, Substance Withdrawal,Syndromes, Substance Withdrawal,Withdrawal Symptom,Withdrawal Symptom, Drug,Withdrawal Symptoms, Drug,Withdrawal Syndrome, Substance,Withdrawal Syndromes, Substance

Related Publications

J Jittiwutikan, and M Srisurapanont, and N Jarusuraisin
October 1983, Presse medicale (Paris, France : 1983),
J Jittiwutikan, and M Srisurapanont, and N Jarusuraisin
January 1997, Alcohol and alcoholism (Oxford, Oxfordshire),
J Jittiwutikan, and M Srisurapanont, and N Jarusuraisin
September 1995, The British journal of psychiatry : the journal of mental science,
J Jittiwutikan, and M Srisurapanont, and N Jarusuraisin
September 2001, Stroke,
J Jittiwutikan, and M Srisurapanont, and N Jarusuraisin
January 2002, European journal of clinical pharmacology,
J Jittiwutikan, and M Srisurapanont, and N Jarusuraisin
January 2014, Journal of affective disorders,
J Jittiwutikan, and M Srisurapanont, and N Jarusuraisin
November 2009, Lancet (London, England),
J Jittiwutikan, and M Srisurapanont, and N Jarusuraisin
January 2010, Journal of neurology, neurosurgery, and psychiatry,
J Jittiwutikan, and M Srisurapanont, and N Jarusuraisin
November 1997, Arzneimittel-Forschung,
J Jittiwutikan, and M Srisurapanont, and N Jarusuraisin
March 2001, Scandinavian journal of primary health care,
Copied contents to your clipboard!